US considers use of expired monkeypox vaccines amid rising demand for doses
As the US looks to stretch its stockpile of Bavarian Nordic’s monkeypox vaccine, regulators are working with the company to assess whether some expired doses can still be used.
Bavarian Nordic CEO Paul Chaplin told Reuters on Wednesday that about half a million expired doses in the US’ national stockpile may still be viable, though it would be up to regulators to make the final call.
An FDA spokesperson confirmed to Endpoints News that it is “actively working with Bavarian Nordic and ASPR/BARDA to obtain the necessary information to potentially requalify a subset of expired doses that meet certain quality specifications.” The New York Times recently reported that about 20 million doses of the vaccine have expired in the US national stockpile.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.